MedPath

Eritoran

Generic Name
Eritoran
Drug Type
Small Molecule
Chemical Formula
C66H126N2O19P2
CAS Number
185955-34-4
Unique Ingredient Identifier
551541VI0Y
Background

Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

Indication

Investigated for use/treatment in sepsis and septicemia.

Clinical Trials
Related News

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase 3
Recruiting
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Other: No systemic corticosteroid
Other: No antiviral agent for COVID-19
Other: No immune modulation for COVID-19
Drug: Standard course macrolide
Other: No antiviral agent for influenza
Drug: Local standard venous thromboprophylaxis
Other: No immunoglobulin
Other: No simvastatin
Other: No cysteamine
Other: No Immune Modulator for Influenza
Other: No vitamin C
Other: No antiplatelet
Procedure: Clinician-preferred mechanical ventilation strategy
Other: No renin-angiotensin system inhibitor
Other: No endothelial modulator
Drug: Extended course macrolide
Biological: Convalescent plasma
Drug: Therapeutic dose anticoagulation
Procedure: Protocolised mechanical ventilation strategy
Drug: P2Y12 inhibitor
Drug: Conventional low dose thromboprophylaxis
Biological: Delayed administration of convalescent plasma
Drug: Intermediate dose thromboprophylaxis
Drug: ARB + DMX-200
Drug: Amoxicillin-clavulanate
Drug: Continuation of therapeutic dose anticoagulation
First Posted Date
2016-04-13
Last Posted Date
2024-07-12
Lead Sponsor
UMC Utrecht
Target Recruit Count
20000
Registration Number
NCT02735707
Locations
🇨🇦

Toronto Western Hospital, Toronto, Ontario, Canada

🇺🇸

University of Illinois Health, Chicago, Illinois, United States

🇦🇺

Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia

and more 405 locations

The Role of TLR4 on Lipid-induced Insulin Resistance

Phase 2
Completed
Conditions
Insulin Sensitivity
Interventions
Drug: D5W (5% Dextrose in water)
First Posted Date
2014-12-22
Last Posted Date
2019-10-08
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
10
Registration Number
NCT02321111
Locations
🇺🇸

Audie L. Murphy VA Hospital, STVHCS, San Antonio, Texas, United States

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

Phase 2
Terminated
Conditions
Insulin Sensitivity
Interventions
Drug: D5W
First Posted Date
2014-10-17
Last Posted Date
2020-03-04
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
15
Registration Number
NCT02267317
Locations
🇺🇸

Audie L. Murphy VA Hospital, STVHCS, San Antonio, Texas, United States

A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Phase 1
Terminated
Conditions
Leukemia
Interventions
First Posted Date
2008-09-22
Last Posted Date
2014-07-11
Lead Sponsor
Eisai Inc.
Target Recruit Count
30
Registration Number
NCT00756912
Locations
🇺🇸

Case Western Reserve University School of Medicine, Cleveland, Ohio, United States

ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis

Phase 3
Completed
Conditions
Severe Sepsis
Interventions
Drug: Placebo
First Posted Date
2006-06-08
Last Posted Date
2017-07-25
Lead Sponsor
Eisai Inc.
Target Recruit Count
2000
Registration Number
NCT00334828

A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

Phase 2
Completed
Conditions
Sepsis
Shock, Septic
Sepsis Syndrome
Septicemia
Infection
First Posted Date
2002-09-20
Last Posted Date
2005-12-12
Lead Sponsor
Eisai Inc.
Target Recruit Count
300
Registration Number
NCT00046072
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy